{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028283","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.968819+00:00","generated_at":"2026-05-31T19:36:17.944914+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor","bullets":["CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.","No serious adverse events, severe TEAEs, or clinically significant lab/ECG findings; all 48 participants completed.","CDI-988 targets a conserved 3CL protease region; potential first dual broad-spectrum treatment for norovirus and coronavirus.","MAD cohort enrollment planned to start in Q4 2024; drug product currently being manufactured.","Norovirus causes ~21M US cases/year; no approved antiviral or vaccine for norovirus."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028283","json":"https://secwatch.observer/filing/0001493152-24-028283.json","markdown":"https://secwatch.observer/filing/0001493152-24-028283.md","text":"https://secwatch.observer/filing/0001493152-24-028283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224028283/0001493152-24-028283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224028283/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:36:17.944914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}